{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:23:58Z","timestamp":1787066638293,"version":"build-2736575974"},"reference-count":54,"publisher":"The Endocrine Society","issue":"8","license":[{"start":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T00:00:00Z","timestamp":1590537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7182050"],"award-info":[{"award-number":["7182050"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Beijing Hospitals Authority Youth Programme","award":["QML20181202"],"award-info":[{"award-number":["QML20181202"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>The contribution of blood extracellular vesicular (EV) programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) in papillary thyroid cancer (PTC) is uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We sought to determine the relationship of EV PD-L1\/PD-1 with the clinical features of pediatric PTC and the role of EV PD-L1 in immunosuppression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>Plasma levels of EV and soluble PD-L1 and PD-1 and levels of plasma cytokines in children with PTC and controls were determined by enzyme-linked immunosorbent assay. Levels of tumor PD-L1 and the tumor-infiltrating lymphocyte (TIL) score were determined by immunohistochemistry. Correlations of the plasma PD-L1\/PD-1 level with clinicopathological characteristics, levels of plasma cytokines, tumor PD-L1 expression, and TIL score were analyzed. T-cell suppression by EVs from PTC patients was determined by incubation of PD-L1high or PD-L1low EVs with activated CD8+ T cells. Changes in CD69 and PD-1 expression and changes in tumor necrosis factor-\u03b1 (TNF\u03b1) and interferon-\u03b3 (IFN\u03b3) secretion were measured by flow cytometry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The levels of plasma PD-L1\/PD-1 were significantly higher in children with PTC than in controls. The levels of plasma EV PD-L1 significantly correlated with tumor T stage, tumor PD-L1 expression, TIL score, and plasma cytokine content. Levels of plasma soluble PD-1 significantly correlated with patient age, plasma EV PD-L1, and IFN\u03b1 concentration. PD-L1high EVs significantly inhibited the activation of CD8+ T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Plasma levels of EV PD-L1, but not soluble PD-L1, were associated with tumor T stage in children with PTC. Plasma EV PD-L1 emerges as a useful metric for assessing tumor T stage and T cell suppression in PTC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa309","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T08:30:01Z","timestamp":1590568201000},"page":"e2970-e2981","source":"Crossref","is-referenced-by-count":27,"title":["EV PD-L1 is Correlated With Clinical Features and Contributes to T Cell Suppression in Pediatric Thyroid Cancer"],"prefix":"10.1210","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9191-6166","authenticated-orcid":false,"given":"Guoliang","family":"Wang","sequence":"first","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lejian","family":"He","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Pathology, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengcai","family":"Wang","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Pathology, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhen","family":"Li","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyin","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nian","family":"Sun","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tai","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ni","sequence":"additional","affiliation":[{"name":"Beijing Children\u2019s Hospital, Capital Medical University, National Center for Children\u2019s Health (NCCH), Beijing, China"},{"name":"Department of Otorhinolaryngology, Head and Neck Surgery, Beijing Children\u2019s Hospital, Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,5,27]]},"reference":[{"issue":"1","key":"2020091101335624400_CIT0001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin."},{"issue":"1","key":"2020091101335624400_CIT0002","doi-asserted-by":"crossref","first-page":"13","DOI":"10.21147\/j.issn.1000-9604.2018.01.02","article-title":"Cancer incidence in Beijing, 2014","volume":"30","author":"Liu","year":"2018","journal-title":"Chin J Cancer Res."},{"issue":"2","key":"2020091101335624400_CIT0003","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.ecl.2016.02.002","article-title":"Thyroid Cancer in Pediatrics","volume":"45","author":"Machac","year":"2016","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"6","key":"2020091101335624400_CIT0004","doi-asserted-by":"crossref","first-page":"R311","DOI":"10.1530\/ERC-15-0381","article-title":"Are we really at the dawn of understanding sporadic pediatric thyroid carcinoma?","volume":"22","author":"Cordioli","year":"2015","journal-title":"Endocr Relat Cancer."},{"issue":"10061","key":"2020091101335624400_CIT0005","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1016\/S0140-6736(16)30172-6","article-title":"Thyroid cancer","volume":"388","author":"Cabanillas","year":"2016","journal-title":"Lancet."},{"issue":"9","key":"2020091101335624400_CIT0006","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1172\/JCI80011","article-title":"Anti-PD-1\/PD-L1 therapy of human cancer: past, present, and future","volume":"125","author":"Chen","year":"2015","journal-title":"J Clin Invest."},{"issue":"5","key":"2020091101335624400_CIT0007","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer."},{"issue":"15","key":"2020091101335624400_CIT0008","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"Jama."},{"issue":"6332","key":"2020091101335624400_CIT0009","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science."},{"key":"2020091101335624400_CIT0010","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"Onco Targets Ther."},{"issue":"6","key":"2020091101335624400_CIT0011","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1084\/jem.20112741","article-title":"Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2","volume":"209","author":"Yokosuka","year":"2012","journal-title":"J Exp Med."},{"issue":"4","key":"2020091101335624400_CIT0012","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell."},{"issue":"19","key":"2020091101335624400_CIT0013","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol."},{"key":"2020091101335624400_CIT0014","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1146\/annurev-med-092012-112807","article-title":"Immune modulation in cancer with antibodies","volume":"65","author":"Page","year":"2014","journal-title":"Annu Rev Med."},{"issue":"1","key":"2020091101335624400_CIT0015","doi-asserted-by":"crossref","first-page":"e1365209","DOI":"10.1080\/2162402X.2017.1365209","article-title":"PD-L1 inhibitors in the pipeline: Promise and progress","volume":"7","author":"Vanella","year":"2017","journal-title":"Oncoimmunology."},{"key":"2020091101335624400_CIT0016","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of Response and Progression to Immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"1","key":"2020091101335624400_CIT0017","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1158\/1078-0432.CCR-17-1261","article-title":"Head and Neck Carcinoma Immunotherapy: Facts and Hopes","volume":"24","author":"Whiteside","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2020091101335624400_CIT0018","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ccell.2016.10.009","article-title":"Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis","volume":"30","author":"Becker","year":"2016","journal-title":"Cancer Cell."},{"issue":"16","key":"2020091101335624400_CIT0019","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1158\/1078-0432.CCR-16-2819","article-title":"Suppression of Lymphocyte Functions by Plasma Exosomes Correlates with Disease Activity in Patients with Head and Neck Cancer","volume":"23","author":"Ludwig","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2020091101335624400_CIT0020","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1172\/JCI81136","article-title":"Exosomes and tumor-mediated immune suppression","volume":"126","author":"Whiteside","year":"2016","journal-title":"J Clin Invest."},{"issue":"7718","key":"2020091101335624400_CIT0021","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature."},{"issue":"3","key":"2020091101335624400_CIT0022","doi-asserted-by":"crossref","first-page":"eaar2766","DOI":"10.1126\/sciadv.aar2766","article-title":"Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles","volume":"4","author":"Ricklefs","year":"2018","journal-title":"Sci Adv."},{"issue":"4","key":"2020091101335624400_CIT0023","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1158\/1078-0432.CCR-17-2664","article-title":"Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients","volume":"24","author":"Theodoraki","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"8","key":"2020091101335624400_CIT0024","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","article-title":"Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth","volume":"28","author":"Yang","year":"2018","journal-title":"Cell Res."},{"key":"2020091101335624400_CIT0025","doi-asserted-by":"crossref","first-page":"24679","DOI":"10.1038\/srep24679","article-title":"Analyses of Endothelial Cells and Endothelial Progenitor Cells Released Microvesicles by Using Microbead and Q-dot Based Nanoparticle Tracking Analysis","volume":"6","author":"Wang","year":"2016","journal-title":"Sci Rep."},{"issue":"11","key":"2020091101335624400_CIT0026","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1007\/s00405-018-5118-x","article-title":"Up-regulated lipocalin-2 in pediatric thyroid cancer correlated with poor clinical characteristics","volume":"275","author":"Tai","year":"2018","journal-title":"Eur Arch Otorhinolaryngol."},{"issue":"7","key":"2020091101335624400_CIT0027","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1210\/jc.2015-4227","article-title":"Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer","volume":"101","author":"Bastman","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"key":"2020091101335624400_CIT0028","doi-asserted-by":"crossref","first-page":"36378","DOI":"10.1038\/srep36378","article-title":"Impaired T Cell-dependent Humoral Immune Response Associated with Juvenile-onset Recurrent Respiratory Papillomatosis Progression","volume":"6","author":"Wu","year":"2016","journal-title":"Sci Rep."},{"key":"2020091101335624400_CIT0029","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.imlet.2017.08.026","article-title":"Enhanced TH2-like peripheral adaptive immune responses in Juvenile-onset Recurrent Respiratory Papillomatosis (JORRP)","volume":"191","author":"Xiao","year":"2017","journal-title":"Immunol Lett."},{"issue":"6","key":"2020091101335624400_CIT0030","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1158\/2326-6066.CIR-16-0329","article-title":"Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade","volume":"5","author":"Zhou","year":"2017","journal-title":"Cancer Immunol Res."},{"issue":"1","key":"2020091101335624400_CIT0031","first-page":"30","article-title":"Diagnosis and treatment of patients with thyroid cancer","volume":"8","author":"Nguyen","year":"2015","journal-title":"Am Health Drug Benefits."},{"issue":"7","key":"2020091101335624400_CIT0032","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med."},{"key":"2020091101335624400_CIT0033","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3389\/fendo.2015.00176","article-title":"Molecular Targeted Therapies of Aggressive Thyroid Cancer","volume":"6","author":"Ferrari","year":"2015","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"2020091101335624400_CIT0034","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1530\/ERC-12-0313","article-title":"Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation","volume":"20","author":"Cunha","year":"2013","journal-title":"Endocr Relat Cancer."},{"issue":"10","key":"2020091101335624400_CIT0035","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1634\/theoncologist.2017-0096","article-title":"Exceptional Response with Immunotherapy in a Patient with Anaplastic Thyroid Cancer","volume":"22","author":"Kollipara","year":"2017","journal-title":"Oncologist."},{"issue":"16","key":"2020091101335624400_CIT0036","doi-asserted-by":"crossref","first-page":"3934","DOI":"10.3390\/ijms20163934","article-title":"The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition","volume":"20","author":"Varricchi","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2020091101335624400_CIT0037","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s12885-019-5380-3","article-title":"Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer","volume":"19","author":"Mehnert","year":"2019","journal-title":"BMC Cancer."},{"key":"2020091101335624400_CIT0038","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2016.08.001","article-title":"Increase in soluble PD-1 is associated with prolonged survival in patients with advanced EGFR-mutated non-small cell lung cancer treated with erlotinib","volume":"100","author":"Sorensen","year":"2016","journal-title":"Lung Cancer."},{"issue":"5","key":"2020091101335624400_CIT0039","doi-asserted-by":"crossref","first-page":"e1310358","DOI":"10.1080\/2162402X.2017.1310358","article-title":"Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer","volume":"6","author":"Kruger","year":"2017","journal-title":"Oncoimmunology."},{"key":"2020091101335624400_CIT0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ejca.2016.03.002","article-title":"High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis","volume":"59","author":"Finkelmeier","year":"2016","journal-title":"Eur J Cancer."},{"issue":"1","key":"2020091101335624400_CIT0041","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble immune checkpoints in cancer: production, function and biological significance","volume":"6","author":"Gu","year":"2018","journal-title":"J Immunother Cancer."},{"issue":"2","key":"2020091101335624400_CIT0042","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.cell.2019.02.016","article-title":"Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory","volume":"177","author":"Poggio","year":"2019","journal-title":"Cell."},{"key":"2020091101335624400_CIT0043","doi-asserted-by":"crossref","first-page":"1956740","DOI":"10.1155\/2016\/1956740","article-title":"Thyroid-Specific Genes Expression Uncovered Age-Related Differences in Pediatric Thyroid Carcinomas","volume":"2016","author":"Cordioli","year":"2016","journal-title":"Int J Endocrinol."},{"issue":"5","key":"2020091101335624400_CIT0044","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2017.74.5497","article-title":"Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer","volume":"36","author":"Shen","year":"2018","journal-title":"J Clin Oncol."},{"key":"2020091101335624400_CIT0045","doi-asserted-by":"crossref","first-page":"117247","DOI":"10.1016\/j.lfs.2019.117247","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with metastasis and differentiation in gastric cancer","volume":"242","author":"He","year":"2020","journal-title":"Life Sci."},{"issue":"1","key":"2020091101335624400_CIT0046","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrc1252","article-title":"Cytokines in cancer pathogenesis and cancer therapy","volume":"4","author":"Dranoff","year":"2004","journal-title":"Nat Rev Cancer."},{"issue":"6","key":"2020091101335624400_CIT0047","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2020091101335624400_CIT0048","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.febslet.2005.12.093","article-title":"Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274)","volume":"580","author":"Lee","year":"2006","journal-title":"FEBS Lett."},{"issue":"1","key":"2020091101335624400_CIT0049","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood."},{"issue":"6","key":"2020091101335624400_CIT0050","doi-asserted-by":"crossref","first-page":"e1168556","DOI":"10.1080\/2162402X.2016.1168556","article-title":"The immune network in thyroid cancer","volume":"5","author":"Galdiero","year":"2016","journal-title":"Oncoimmunology."},{"issue":"1","key":"2020091101335624400_CIT0051","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13000-017-0662-z","article-title":"PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma","volume":"12","author":"Bai","year":"2017","journal-title":"Diagn Pathol."},{"issue":"3","key":"2020091101335624400_CIT0052","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4158\/EP-2018-0342","article-title":"Programmed cell death-ligand 1 overexpression in thyroid cancer","volume":"25","author":"Zhang","year":"2019","journal-title":"Endocr Pract."},{"issue":"12","key":"2020091101335624400_CIT0053","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1055\/a-0648-4593","article-title":"Thyroid autoimmunity and thyroid cancer - the pathogenic connection: a 2018 update","volume":"50","author":"Nagayama","year":"2018","journal-title":"Horm Metab Res."},{"key":"2020091101335624400_CIT0054","doi-asserted-by":"crossref","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","article-title":"Analysis of the PD-1\/PD-L1 axis in human autoimmune thyroid disease: Insights into pathogenesis and clues to immunotherapy associated thyroid autoimmunity","volume":"103","author":"\u00c1lvarez-Sierra","year":"2019","journal-title":"J Autoimmun."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa309\/33314970\/dgaa309.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/105\/8\/e2970\/33733566\/dgaa309.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/105\/8\/e2970\/33733566\/dgaa309.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T01:34:24Z","timestamp":1599788064000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/105\/8\/e2970\/5847668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,27]]},"references-count":54,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa309","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,5,27]]}}}